Scilex Holding Company (SCLX) announced on Wednesday that it has authorized its management team to explore various strategic options to enhance the value of its wholly owned subsidiary, Scilex Pharma.
These options may involve spinning off or publicly listing Scilex Pharma's securities on international markets and exchanges, such as those in Hong Kong. Additionally, the company is considering a potential strategic maneuver or distributing Scilex Pharma's common stock as a dividend to its existing shareholders.
Scilex Pharma introduced its inaugural commercial offering, ZTlido (lidocaine topical system), in October 2018. This prescription lidocaine topical system is developed with innovative technology to overcome the limitations of current lidocaine therapies by ensuring superior adhesion and delivering consistent pain relief during the entire 12-hour application period.
